Ameriprise
AMLX icon

Ameriprise’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ameriprise’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-502,366
Closed -$6.07M – 4052
2025
Q4 		$6.07M Buy
502,366
+368,858
+276% +$5.01M ﹤0.01% 2302
2025
Q3 		$1.81M Buy
133,508
+38,289
+40% +$360K ﹤0.01% 3055
2025
Q2 		$610K Buy
95,219
+82,414
+644% +$401K ﹤0.01% 3456
2025
Q1 		$45.3K Sell
12,805
-37,623
-75% -$134K ﹤0.01% 3947
2024
Q4 		$191K Buy
+50,428
New +$237K ﹤0.01% 3878
2023
Q4 		– Sell
-129,918
Closed -$2.38M – 3898
2023
Q3 		$2.38M Sell
129,918
-254
-0.2% -$5.37K ﹤0.01% 2742
2023
Q2 		$2.81M Sell
130,172
-82,281
-39% -$2.22M ﹤0.01% 2703
2023
Q1 		$6.23M Buy
212,453
+8,377
+4% +$291K ﹤0.01% 2165
2022
Q4 		$7.54M Buy
204,076
+136,201
+201% +$4.83M ﹤0.01% 1987
2022
Q3 		$1.91M Sell
67,875
-31,080
-31% -$775K ﹤0.01% 2804
2022
Q2 		$1.91M Buy
98,955
+16,645
+20% +$198K ﹤0.01% 2830
2022
Q1 		$1.06M Buy
+82,310
New +$1.86M ﹤0.01% 3191

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Ameriprise's AMLX Position: Q1 2026 in Review

Ameriprise sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 502,366 shares — an estimated $6.07M sold.

Ameriprise first reported a position in AMLX in Q1 2022 and held it in 12 quarters. The position peaked at $7.54M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Ameriprise reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 502,366 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $6.07M.
  • Ameriprise first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 12 quarters.
  • Ameriprise's Amylyx Pharmaceuticals position peaked at $7.54M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.